-
公开(公告)号：US11702409B2
公开(公告)日：2023-07-18
申请号：US17125335
申请日：2020-12-17
Applicant: NOVARTIS AG
Inventor： Simona Cotesta , Marc Gerspacher , Catherine Leblanc , Edwige Liliane Jeanne Lorthiois , Bo Liu , Rainer Machauer , Robert Mah , Christophe Mura , Pascal Rigollier , Nadine Schneider , Stefan Stutz , Andrea Vaupel , Nicolas Warin , Rainer Wilcken
IPC: C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
CPC classification number: C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07B2200/13
Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof;
a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.-
公开(公告)号：US10786492B2
公开(公告)日：2020-09-29
申请号：US16211139
申请日：2018-12-05
Applicant: Novartis AG
Inventor： Nicole Buschmann , Robin Alec Fairhurst , Pascal Furet , Thomas Knoepfel , Catherine Leblanc , Robert Mah
IPC: C07D401/12 , C07D401/14 , A61K31/444 , A61K31/4427 , C07D213/75 , C07D405/14 , A61P35/00 , A61K31/497
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
-
公开(公告)号：US10130629B2
公开(公告)日：2018-11-20
申请号：US15561209
申请日：2016-03-23
Applicant: Novartis AG
Inventor： Nicole Buschmann , Robin Alec Fairhurst , Jorge Garcia Fortanet , Pascal Furet , Diana Graus Porta , Nafeeza Hafeez , Bo Han , Thomas Knoepfel , Matthew J. LaMarche , Catherine Leblanc , Lv Liao , Robert Mah , Dale Porter , Can Wang , Markus Wartmann , Jing Xiong , Xianglin Zhao
IPC: A61K31/496 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5377
Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
-
公开(公告)号：US20190105309A1
公开(公告)日：2019-04-11
申请号：US16211139
申请日：2018-12-05
Applicant: Novartis AG
Inventor： Nicole Buschmann , Robin Alec Fairhurst , Pascal Furet , Thomas Knoepfel , Catherine Leblanc , Robert Mah
IPC: A61K31/444 , A61K31/497 , A61P35/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
-
Patent Agency Ranking
公开(公告)号：US20220363670A1
公开(公告)日：2022-11-17
申请号：US17125335
申请日：2020-12-17
Applicant: NOVARTIS AG
Inventor： Simona Cotesta , Marc Gerspacher , Catherine Leblanc , Edwige Liliane Jeanne Lorthiois , Bo Liu , Rainer Machauer , Robert Mah , Christophe Mura , Pascal Rigollier , Nadine Schneider , Stefan Stutz , Andrea Vaupel , Nicolas Warin , Rainer Wilcken
IPC: C07D403/14 , C07D405/14 , C07D417/14 , C07D401/14 , C07D471/04 , C07D413/14 , C07D487/04
Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
-
公开(公告)号：US20140350010A1
公开(公告)日：2014-11-27
申请号：US14361068
申请日：2012-11-28
Applicant: NOVARTIS AG
Inventor： Pascal Furet , Vito Guagnano , Philipp Holzer , Robert Mah , Keiichi Masuya , Achim Schlapbach , Stefan Stutz , Andrea Vaupel
IPC: C07D487/04 , A61K31/4178 , A61K31/4162 , A61K31/4709 , A61K31/506 , A61K31/41 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/4439 , A61K31/519
CPC classification number: C07D487/04 , A61K31/41 , A61K31/4162 , A61K31/4178 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5377
Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
Abstract translation: 本发明涉及本文所述的式（I）化合物，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的化合物的用途和用途，以及组合 包括这样的化合物。
-
![Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases](/abs-image/US/2014/08/26/US08815926B2/abs.jpg.150x150.jpg)
7.发明授权Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases 有权取代的吡咯并[3,4-D]咪唑用于治疗MDM2 / 4介导的疾病公开(公告)号：US08815926B2
公开(公告)日：2014-08-26
申请号：US13748790
申请日：2013-01-24
Applicant: Novartis AG
Inventor： Pascal Furet , Vito Guagnano , Philipp Holzer , Joerg Kallen , Lv Liao , Robert Mah , Liang Mao , Keiichi Masuya , Achim Schlapbach , Stefan Stutz , Andrea Vaupel
IPC: A61K31/4188 , C07D235/02 , C07D487/04 , A61K45/06 , A61K31/541 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/501
CPC classification number: C07D487/04 , A61K31/4188 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06
Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。
-
公开(公告)号：US10507201B2
公开(公告)日：2019-12-17
申请号：US16289612
申请日：2019-02-28
Applicant: NOVARTIS AG
Inventor： Nicole Buschmann , Robin Alec Fairhurst , Pascal Furet , Diana Graus Porta , Carolina Haefliger , Bo Han , Thomas Knöpfel , Catherine Leblanc , Lv Liao , Robert Mah , Masato Murakami , Pierre Nimsgern , Michael Palmer , Dale Porter , Sebastien Ripoche , Can Wang , Youzhen Wang , Andreas Weiss , Jing Xiong , Xianglin Zhao
IPC: A61K31/475 , A61K31/4545 , A61K31/496 , A61K31/55 , A61P35/00 , A61K31/4375
Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
-
![Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction](/abs-image/US/2017/01/31/US09556180B2/abs.jpg.150x150.jpg)
9.发明授权Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction 有权吡唑并[3,4-d]嘧啶酮化合物作为P53 / MDM2相互作用的抑制剂公开(公告)号：US09556180B2
公开(公告)日：2017-01-31
申请号：US14762051
申请日：2014-01-21
Applicant: Novartis AG
Inventor： Pascal Furet , Vito Guagnano , Philipp Holzer , Joerg Kallen , Robert Mah , Keiichi Masuya , Achim Schlapbach , Andrea Vaupel
IPC: C07D487/04 , A61K31/519
CPC classification number: C07D487/04 , A61K31/519
Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.029 seconds)
